Alex Khan
Corporate Vice President and Investor Relations
Replay available
Absci Corporation (NASDAQ: ABSI) Q2 2026 earnings conference call, held 2026-08-11. Replay captured from the company's public earnings webcast.

Corporate Vice President and Investor Relations
Founder and CEO
Chief Medical Officer, Head of R&D
Chief Financial Officer and Chief Business Officer
Analyst, J.P. Morgan
Analyst, TD Cowen
Analyst, Guggenheim Securities
Good day, and thank you for standing by. Welcome to the Absci Second Quarter Business Update. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Alex Kahn, Corporate Vice President and Investor Relations. Please go ahead. Thank you. Earlier today, Absci released financial and operating results for the quarter ended 06/30/2026. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to investorsabsci dot com. An archived webcast of this call will be available for replay on Absci's Investor Relations website at investors.absci.com for at least ninety days after this call. Joining me today are Sean McLean, Absci's Founder and CEO Zach Jonizen, Chief Financial Officer and Chief Business Officer and Ronti Somrodhni, Chief Medical Officer, Head of R and D. Before we begin, I'd like to remind you that management will make statements during this call that are forward looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. You should not place undue reliance on forward looking statements. These include statements regarding the development and clinical progress of our pipeline programs, including ABS201, the design, enrollment conduct and timeli...